

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6927442

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	KUROS BIOSCIENCES AG	08/24/2021
RECEIVING PARTY DATA		
Name:	KUROS US LLC	
Street Address:	1209 ORANGE STREET	
Internal Address:	CORPORATION TRUST CENTER	
City:	WILMINGTON	
State/Country:	DELAWARE	
Postal Code:	19801	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	9902972
CORRESPONDENCE DATA		
Fax Number:	(703)712-8525	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(703) 712-8531	
Email:	admin@medlerferro.com, docketing@medlerferro.com	
Correspondent Name:	MEDLER FERRO WOODHOUSE & MILLS PLLC	
Address Line 1:	8201 GREENSBORO DRIVE	
Address Line 2:	SUITE 1060	
Address Line 4:	MCLEAN, VIRGINIA 22102	
ATTORNEY DOCKET NUMBER:	9902972	
NAME OF SUBMITTER:	CYNTHIA M. BOUCHEZ	
SIGNATURE:	/Cynthia M. Bouchez/	
DATE SIGNED:	09/21/2021	
Total Attachments: 2		
source=US 9902972 - Assignment - Kuros Biosciences AG to Kuros US LLC#page1.tif		
source=US 9902972 - Assignment - Kuros Biosciences AG to Kuros US LLC#page2.tif		

ASSIGNMENT

In consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned **Kuros Biosciences AG** (the Assignor) hereby sells and assigns to **Kuros US LLC** (the Assignee), a corporation having a principle place of business at 1209 Orange Street, Corporation Trust Center, Wilmington, DE 19801, United States, their entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **PROCESSES FOR PACKAGING OLIGONUCLEOTIDES INTO VIRUS-LIKE PARTICLES OF RNA BACTERIOPHAGES** for which application for patent in the United States of America was filed on **July 18, 2013**, also known as United States Application No. **13/945,708**, now **United States Patent No. 9,902,972**, issued **February 27, 2018** in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, international applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions and discoveries described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned agrees to execute all papers necessary in connection with the applications and any non-provisional, international, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned agrees to execute all papers necessary in connection with any derivation or patent enforcement action (judicial or otherwise) related to the applications or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.


The undersigned hereby represents that he has full right to convey the entire interest herein assigned, and that he has not executed, and will not execute, any agreement in conflict therewith.

The undersigned hereby grants the attorneys associated with Customer Number 56719 power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


IN WITNESS WHEREOF, executed by the undersigned on the date opposite his name.

Date: August 24, 2021

Signature of Representative: _____


Philippe SAUDAN, Chief Development Officer
Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren, Switzerland

Signature of Representative: _____


Alistair IRVINE, Chief Business Officer
Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren, Switzerland